Nov. 14, 2022Dr. David Akbari Receives Prestigious ADA Hearing Industry Leadership AwardHHTMNo excerpt
Nov. 14, 2022Tobias Bartels: EUHA’s new Managing DirectorHHTMAt the beginning of November, Tobias Bartels took up his new position as the European Union of Hearing Aid Acousticians’ new managing director. The 48-year-old business graduate brings to bear more than 25 years of experience from positions held in international companies in a wide variety of industries. His main focus has been in the fields of marketing and sales, digitization, conventions
Nov. 13, 2022Researchers Find Undetectable Low Frequency Sounds Increased Dancing at Live ConcertHHTMHAMILTON, ONTARIO — Researchers studying how different aspects of music influence the body turned a live electronic music concert into a lab study. By introducing levels of bass over speakers that were too low to hear and monitoring the crowd’s movements, scientists found that people danced 11.8 percent more when the very low frequency bass was present. The study appears Monday
Nov. 11, 2022Signia Holds National Sales Meeting; Helps Raise Thousands for CharityHHTMPISCATAWAY, NEW JERSEY — Capping a year of highly successful new product and program introductions, Signia took the stage before 150+ attendees at its 2022 National Sales Meeting from October 10 – 13 at JW Marriott Orlando, Grande Lakes and pledged to continue the momentum in 2023 by providing partners and patients with a ‘Brilliant Fit’ that goes beyond innovative
Nov. 10, 2022Convey Health Solutions Announces Partnership with Birdsong Hearing Benefits™HHTMJACKSONVILLE, FLORIDA — Birdsong Hearing Benefits™ has announced a partnership with Convey Health Solutions to serve as its preferred hearing benefits manager. Convey, based in Ft. Lauderdale, Fla., is a leading provider of technology and services to support healthcare organizations and individuals in the Medicare markets. Through this partnership Birdsong will deliver hearing benefit services as a third-party administrator. These services
Nov. 09, 2022Frequency Therapeutics Provides Business Updates and Q3 2022 Financial ResultsHHTMLEXINGTON, MASSACHUSSETTS — Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the third quarter ended September 30, 2022. “This past quarter has been one of momentum and execution. With the completion of enrollment for the Phase 2b
Nov. 09, 2022Signia to Hold Second Virtual Student EventHHTMPISCATAWAY, NEW JERSEY – Signia today announced that it is holding its second virtual Signia Student University (SSU) event, featuring several in-depth and interactive sessions that deliver key insights and knowledge for audiology doctorate program students. The free program will kick-off with a live welcome event on December 6th at 6:00 pm ET led by Mike O’Neil, President of Signia
Nov. 08, 2022Decibel Therapeutics Announces Submission of Clinical Trial Applications for Lead Gene Therapy Candidate DB-OTOHHTMBOSTON, MASSACHUSSETTS — Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, has announced the submission of Clinical Trial Applications (CTAs) to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom and the Spanish Agency of Medicines and Medical Devices (AEMPS) for a Phase
Nov. 07, 2022FDA Grants Rare Pediatric Disease Designation to Sensorion’s OTOF-GT for the Treatment of Otoferlin Gene-Mediated Hearing LossHHTMMONTPELLIER, FRANCE — Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, announces that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to the Company’s lead therapy gene candidate, OTOF-GT, a gene therapy intended for the treatment of otoferlin
Nov. 06, 2022Altamira Therapeutics Announces Divestiture of Inner Ear Development AssetsHHTMHAMILTON, BERMUDA — Altamira Therapeutics Ltd. (formerly known as Auris Medical), a company dedicated to developing therapeutics that address important unmet medical needs, has announced that it has entered into an agreement regarding the sale of certain of its legacy assets comprised of its inner ear therapeutics research and development programs and a license to use its RNA delivery technology